Alanine

Alanine

SCHEMBL14764702

C[C@H](N)C(=O)O.C[C@H](N)C(=O)O.C[C@H](N)C(=O)O.C[C@H](N)C(=O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.59
TP53 P04637 1/20 0.53
SLC1A3 P43003 2/20 0.43
SLC1A2 P43004 2/20 0.43
SLC1A1 P43005 1/20 0.43
GABRP O00591 4/20 0.43
GABRD O14764 4/20 0.43
GABRA1 P14867 4/20 0.43
GABRB1 P18505 4/20 0.43
GABRG2 P18507 4/20 0.43
GABRB3 P28472 4/20 0.43
GABRA5 P31644 4/20 0.43
GABRA3 P34903 4/20 0.43
GABRA2 P47869 4/20 0.43
GABRB2 P47870 4/20 0.43
GABRA4 P48169 4/20 0.43
GABRE P78334 4/20 0.43
GABRA6 Q16445 4/20 0.43
GABRG1 Q8N1C3 4/20 0.43
GABRG3 Q99928 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Alanine SCHEMBL43623 1.00
D-Alanine SCHEMBL614024 1.00 SLC7A5 (0.59) SLC7A5TP53SLC1A3SLC1A2SLC1A1
Alanine SCHEMBL10723495 1.00 SLC7A5 (0.59) SLC7A5TP53SLC1A3SLC1A2SLC1A1
Alanine SCHEMBL1332110 1.00
Alanine SCHEMBL31 1.00
Alanine SCHEMBL254290 1.00 SLC7A5 (0.59) SLC7A5TP53SLC1A3SLC1A2SLC1A1
Alanine SCHEMBL2784274 1.00
D-Alanine SCHEMBL2027760 1.00 SLC7A5 (0.59) SLC7A5TP53SLC1A3SLC1A2SLC1A1
Alanine SCHEMBL452350 1.00 SLC7A5 (0.59) SLC7A5TP53SLC1A3SLC1A2SLC1A1
D-Alanine SCHEMBL31040666 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2753691-B1 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INST NAT SANTE RECH MED (FR) 2020-07-22 EP claimed
US-9249406-B2 Mutated tissue plasminogen activators and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2016-02-02 US claimed
US-20150050264-A2 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2015-02-19 US claimed
US-20140212406-A1 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-07-31 US claimed
WO-2013034710-A1 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2013-03-14 WO claimed
US-20230391869-A1 INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES Université de Paris (FR) 2023-12-07 US disclosed
WO-2023156683-A1 TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES ACTICOR BIOTECH (FR) 2023-08-24 WO disclosed
US-11692033-B2 Inhibition of platelet aggregation using anti-human GPVI antibodies ACTICOR BIOTECH (FR) 2023-07-04 US disclosed
EP-2753691-B1 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INST NAT SANTE RECH MED (FR) 2020-07-22 EP disclosed
US-20200138919-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE UNIVERSITÉ PARIS CITÉ (FR) 2020-05-07 US disclosed
WO-2018141909-A1 INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES ACTICOR BIOTECH (FR) 2018-08-09 WO disclosed
US-9732334-B2 Mutated tissue plasminogen activators and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2017-08-15 US disclosed
US-20160194623-A1 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2016-07-07 US disclosed
US-9249406-B2 Mutated tissue plasminogen activators and uses thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2016-02-02 US disclosed
US-20150050264-A2 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2015-02-19 US disclosed
CN-103980348-A Oligopeptide for diagnosing and treating hepatitis B and application of oligopeptide CHONGQING ACADEMY SCI & TECH 2014-08-13 CN disclosed
US-20140212406-A1 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-07-31 US disclosed
WO-2013034710-A1 NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2013-03-14 WO disclosed